Back to announcement
20250509_OMED_Laporan Informasi dan Fakta Material_31884751_lamp2.pdf
Other Text extracted OMEDSource file signed link, expires in 15 minutes
Extracted text 3
Page 1
INVESTOR BULLETIN COMPANY OVERVIEW
OPERATION UPDATE Q1 2025 PT Jayamas Medica Industri Tbk (OMED), established
May 7th 2025 in the early 2000s, has grown into a leading player in
Indonesia’s medical equipment and supplies industry.
Share Price Data (per 5th of May 2025): OMED’s extensive product portfolio includes approximately
6,000 active SKUs, supported by a comprehensive
Ticker on IDX OMED
distribution network that reaches 514 cities across all 34
Last Closing Price (IDR): 160 provinces in Indonesia.
Outstanding Shares: 27,058,850,000
COMPANY HIGHLIGHTS
Market Cap (IDR Bn): 4,329
• PT Jayamas Medica Industri Tbk (OMED) delivered
resilient financial results in Q1 2025, reinforcing its
Shareholder Structure: strong fundamentals in Indonesia’s healthcare
manufacturing sector. Revenue reached IDR 436.3 billion,
PT Intisumber Hasilsempurna (%): 83,30 up from IDR 427.4 billion year-on-year (YoY). Profitability
Yacobus Jemmy Hartanto (%): 0,91 remained solid, with EBITDA rising to IDR 98.4 billion
from IDR 90.5 billion (22.6% vs 21.2% margin) and net
Siane Soetanto (%): 0,90 profit increasing to IDR 73.1 billion from IDR 64.1 billion
(16.8% vs 15.0% margin), supported by operational
Public (%): 14,89
efficiency and disciplined cost control.
• In terms of production, total sales volume grew by
Contact us: 4.21% YoY to 611.3 million units. This expansion was
Corporate Secretary & Investor Relation driven by Biotech & Lab (+41.0%) and Wound Care
(+8.65%), offsetting declines in Diagnostic & Equipment
Phone: +62 811-3075-8028 (Hansen Teguh) (-3.47%) and Hospital Furniture (-35.0%). These results
indicate continued momentum in key segments aligned
Email:
corporate.secretary@onemed.co.id with evolving healthcare needs.
ir@onemed.co.id
• Amid global trade shifts, OMED is gaining export
Website: momentum following the 245% U.S. tariff on
www.onemed.co.id Chinese syringes. With interest from U.S. buyers for large-
scale syringe orders starting 2026, OMED is well-
positioned to enter a new phase of export-led growth and
strengthen its global supply chain role.
Company’s Presence Across Country
Sumatera 1 National Distribution
Center
Kalimantan Sulawesi
23 Branch offices and
warehouses
Maluku
Papua
11 Sales offices
Bali Lombok
Java Flores 28 Omnichannel
Stores
Page 2
Resilient Margins Reflect Operational Strength and
Product Differentiation
Sales and Profitability by Product Segments
In the first quarter of 2025, OMED’s Disposable & Medical
Consumables segment recorded a higher gross margin of
32.9%, supported by increased average selling prices (ASP) and
450,000 50.00%
43.6% 43.0%
41.7%
lower material costs, reinforcing the company’s pricing power
45.00%
400,000
350,000
40.00%
and procurement efficiency. The Wound Care segment delivered
32.9%
300,000
29.9%
35.00%
an even stronger gross margin of 43.6%, driven by higher sales
25.9% 30.00%
volume and reduced production costs, highlighting operational
223,072
improvements and growing demand in core product lines.
250,000
25.00%
200,000
15.7%
20.00%
150,000
15.00%
Meanwhile, Antiseptics & Dialysis Fluid maintained robust
100,000
71,916
performance with a 43.0% gross margin. This was achieved
through an improved product mix—such as higher-volume
10.00%
49,952 42,087
20,487 18,826
contributions from cardio gel and klorsept—and price increases
50,000
9,820
5.00%
in key SKUs like alcohol, povidone, and ecodine. Together, these
0 0.00%
Disp. & Wound Antis & Diagnostic Walk Aids Biotech & Hospital
Med. Cons. Care Dialys Fl. & Equi. Reh. Care Lab Furniture segments illustrate OMED’s ability to scale profitably through a
Sales (IDR Mn) Gross Margin % combination of optimized cost structures and value-added
pricing.
Source: Company’s Internal Data, 1Q2025
OMED Taps US Market as China Tariffs Spark Major
Syringe Export Breakthrough
New Tariff Rates on Selected Goods from China The recent 245% U.S. tariff increase on Chinese
Base Tariff Pre - 2025 Tariff syringes presents a strategic export opportunity for PT
Steel, alumunium, auto Cars, car parts
Fentanyl and reciprocal
Jayamas Medica Industri Tbk (OMED). As U.S. buyers
seek alternatives to Chinese suppliers, OMED has
Syringes 245%
secured a significant syringe export order to the U.S.
starting in 2026—marking a pivotal shift toward export-
driven growth and reinforcing its position in the global
Wool Sweaters 169%
medical supply chain.
Vitamin C 145% This momentum reflects a broader global realignment,
as international buyers diversify sourcing beyond China.
Toys 145% With strong production capacity, cost efficiency, and
adherence to international quality standards, OMED is
Aluminum Outdoor Chairs 75% well-placed to build long-term global partnerships. The
U.S. order not only validates OMED’s global
Door hinges for cars 67%
competitiveness but also opens a new chapter of
growth, expected to generate revenue exceeding USD 1
million beginning in 2026.
Laptops 20%
In 2025, OMED will focus on project validation, tooling
Smartphones 20%
development, and machinery acquisition to ensure
successful execution and scalability of this export
Source: The New York Times initiative.
Page 3
Operational Highlights Unaudited
Production Price
(in thousand units) 1Q 2024 1Q 2025 YoY (in IDR) 1Q 2024 1Q 2025 YoY
Sales Volume Average Selling Price
Disposable & Consumables 365,276 370,758 1.50% Disposable & Consumables 592 602 1.69%
Wound Care 83,783 91,032 8.65% Wound Care 794 790 (0.50%)
Antiseptic & Dialysis Fluid 107,744 108,029 0.26% Antiseptic & Dialysis Fluid 465 462 (0.65%)
Diagnostic & Equipment 721 696 (3.47%) Diagnostic & Equipment 68,261 60,492 (11.38%)
Walking Aids & Rehab 467 468 0.21% Walking Aids & Rehab 41,221 43,739 6.11%
Biotech & Lab 28,583 40,302 41.00% Biotech & Lab 596 467 (21.64%)
Hospital Furniture 451,858 774,997 71.51%
Hospital Furniture 20 13 (35.00%)
Total 586,594 611,298 4.21%
Source: Company’s Internal Data
Financial Highlights
Revenue (In Billion Rupiah) EBITDA (In Billion Rupiah) Net Profit (In Billion Rupiah)
1,886
1,739 1,737
25.0%
20.7% 21.6% 21.2% 22.6% 16.8% 17.2% 16.8%
14.9% 15.0%
434.6
427.4 436.3 359.5 407.3 290.5 259.4 324.0
90.5 98.4 64.1 73.1
2022 2023 2024 1Q24 1Q25 2022 2023 2024 1Q24 1Q25 2022 2023 2024 1Q24 1Q25
EBITDA EBITDA Margin Net Profit Net Profit Margin
Assets (In Billion Rupiah) Liabilities (In Billion Rupiah) Equity (In Billion Rupiah)
2,569
2,826 2,937 2,496
2,507 2,581 2,245
2,069
1,726 466 437 1,245
330 368
438
2021 2022 2023 2024 1Q25 2021 2022 2023 2024 1Q25 2021 2022 2023 2024 1Q25
Source: Company’s Financial Statement
Names mentioned 5 people and organisations named in the text · linked when the evidence is strong
unresolved
org
PT Intisumber Hasilsempurna
p.1
unresolved
org
PT Steel
p.2
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.